The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor.

ABSTRACT: AT13387 is an orally bioavailable clinical candidate developed to inhibit theheat shock protein 90 (Hsp90). This article describes a modified synthetic route for the multi-gram production of AT13387 in 46% overall yield. The modified synthetic route is short, avoids stringent reaction conditions and difficult purifications, which led to increase in an overall yield.

SUBMITTER: Kaur J 

PROVIDER: S-EPMC7577423 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature